Revamped Radius Looks To Cash In With $86 Million IPO

Radius Health has raised more than $250 million from private investors to develop an osteoporosis drug to pit against Eli Lilly’s teriparatide (Forteo). Now, after switching CEOs three times and kicking off a big Phase III trial, the Cambridge, MA-based company will see if it can get the same type of financial support on Wall Street. Radius has become the latest local biotech to file for an IPO.

Help employers find you! Check out all the jobs and post your resume.